In a phase 1 study of patients with IDH1-mutated relapsed/refractory AML, ivosidenib monotherapy achieved a CR/CRi rate of 30.4% with a median duration of response of 8.2 months66. This evidence concerns the gene IDH1 and acute myeloid leukemia.